http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Antitumor Components Isolated from the Heartwood Extract of Dalbergia odorifera
Choi, Chun-Whan,Choi, Yeon-Hee,Cha, Mi-Ran,Kim, Young-Sup,Yon, Gyu-Hwan,Kim, Young-Kyoon,Choi, Sang-Un,Kim, Young-Ho,Ryu, Shi-Yong The Korean Society for Applied Biological Chemistr 2009 Applied Biological Chemistry (Appl Biol Chem) Vol.52 No.4
Ongoing search for promising antitumor components from plant resources, we found that the methanol extract from the heartwood of Dalbergia odorifera (Leguminosae) demonstrated a significant inhibition on the proliferation of human tumor cell lines including multidrug resistant cells in vitro. Intensive bioassay-guided purification of the extract finally led to the isolation of seven flavonoids and two phenolic components as active constituents for antitumor property, in vitro, i.e., medicarpin (1), 2-hydroxy-3,4-dimethoxybenzaldehyde (2), formononetin (3), tectorigenin (4), mucronulatol (5), (3R)-5'-methoxyvestitol (6), hydroxyobtustyrene (7), liquiritigenin (8), and (3R)-calussequinone (9), respectively.
Cha, Jihye,Jeon, Tae-Won,Lee, Chang Geol,Oh, Sang Taek,Yang, Hee-Beom,Choi, Kyung-Ju,Seo, Daekwan,Yun, Ina,Baik, In Hye,Park, Kyung Ran,Park, Young Nyun,Lee, Yun-Han Taylor Francis 2015 International journal of hyperthermia Vol.31 No.7
<P>Modulated electro-hyperthermia (mEHT), also known as oncothermia, shows remarkable treatment efficacies for various types of tumours, including glioma. The aim of the present study was to investigate the molecular mechanism underlying phenotypic changes in oncothermic cancer cells.</P>
${\alpha}$-Glucosidase Inhibitiors from Seed Extract of Paeonia lactiflora
Choi, Chun-Whan,Choi, Yeon-Hee,Cha, Mi-Ran,Park, Jee-Hee,Kim, Young-Sup,Kim, Young-Kyoon,Choi, Sang-Un,Yon, Gyu-Hwan,Hong, Kyung-Sik,Kim, Young-Ho,Ryu, Shi-Yong The Korean Society for Applied Biological Chemistr 2009 Applied Biological Chemistry (Appl Biol Chem) Vol.52 No.6
Alpha-glucosidase inhibitors are oral antihyperglycemic agents that act on alpha-glucosidase competitively, delaying intestinal carbohydrate absorption and lessening postprandial increases in glucose levels. In the search for new classes of ${\alpha}$-glucosidase inhibitors extracted from natural resources, 420 different plant extracts were evaluated for their inhibitory effect on ${\alpha}$-glucosidase, in vitro. Amongst the tested extracts, the seed extract of Paeonia lactiflora (Paeoniaceae) demonstrated a significant degree of inhibition on the enzyme, according to dose. Extensive bioassay-guided fractionation of the extract resulted in the isolation of six materials, luteolin (1), resveratrol (2), trans-${\varepsilon}$-viniferin (3), gnetin H (4), suffruticosol A (5) and suffruticosol B (6), that are active agents for ${\alpha}$-glucosidase inhibition. Resveratrol (2) is a well-known naturally occurring hydroxystilbene, particularly abundant in wine and some related stilbene oligomers. Materials (3-6) exhibited relatively strong inhibition of ${\alpha}$-glucosidase and their $IC_{50}$ values were calculated as: 0.92mM (2), 3.15mM (3), 1.15 mM (4), 2.53mM (5) and 3.15mM (6). In contrast, the ($IC_{50}$) value of the reference drug, acarbose, was estimated as 8.28mM in vitro.
Ran-hui Cha,Su Hyun Kim,Eun Hui Bae,유민아,Beom Soon Choi,최훈영,Sun Woo Kang,Jung-Ho Shin,한상엽,양철우,강덕희 대한신장학회 2019 Kidney Research and Clinical Practice Vol.38 No.3
Background: Hyperuricemia is associated with the development and progression of chronic kidney disease (CKD) as well as cardiovascular diseases. However, there is no consistent recommendation regarding the treatment of asymptomatic hyperuricemia (AHU) in CKD patients. Here, we surveyed Korean physicians’ perceptions regarding the diagnosis and management of AHU in CKD patients. Methods: Questionnaires on the management of AHU in CKD patients were emailed to regular members registered with the Korean Society of Nephrology. Results: A total of 158 members answered the questionnaire. Among the respondents, 49.4%/41.1% were considered hyperuricemic in male CKD patients whereas 36.7%/20.9% were considered hyperuricemic in female CKD patients when defined by serum uric acid level over 7.0/8.0 mg/dL, respectively. A total of 80.4% reported treating AHU in CKD patients. The most important reasons to treat AHU in CKD patients were renal function preservation followed by cerebro-cardiac protection. Majority of respondents (59.5%) thought that uric acid-lowering agents (ULAs) were the most effective method for controlling serum uric acid levels. Approximately 80% chose febuxostat as the preferred medication. A total of 32.3% and 31.0%, respectively, initiated ULA treatment if the serumuric acid level was more than 8.0 or 9.0 mg/dL, respectively. In addition, 39.2% and 30.4% answered that target serum uric acid levels of less than 6.0 or 7.0 mg/dL, respectively, were appropriate. The two major hurdles to prescribing ULAs were concerns of adverse reactions and the existing lack of evidence (i.e., the absence of Korean guidelines). Conclusion: Most Korean physicians treat AHU in CKD patients to prevent CKD progression and cerebrocardiovascular complications.